510(k) Report

510(k) · Cleared

Cleared

Xtag Cystic Fibrosis 39 Kit V2, (CFTR 39 Kit V2), Model I027C0231, I027D0266, I027E0267

K083846510(k) TraditionalCleared Sep 1, 2009251-day reviewClass II21 CFR 866.5900

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Luminex Molecular Diagnostics, Inc. · NUA System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection

Cleared on Sep 1, 2009 as substantially equivalent to DEN050004 (Tm Bioscience Corporation, 2005) and 1 other predicate after a 251-day review. Its family tree reaches back 2 generations to 2005.

Decided
Sep 1, 2009
Review
251 days
Class
Class II
Product code
NUA
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to DEN050004 (2005). No later device cites it as a predicate yet.

  1. Root · 2 generations backDEN050004 Tag-IT Cystic Fibrosis KitTm Bioscience Corporation · 2005
  2. 1 generation backK060627 Tag-IT Cystic Fibrosis KitTm Bioscience Corporation · 2006
  3. This deviceK083846 Xtag Cystic Fibrosis 39 Kit V2, (CFTR 39 Kit V2), Model I027C0231…Luminex Molecular Diagnostics, Inc. · 2009
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN050004Tag-IT Cystic Fibrosis KitTm Bioscience Corporation2005—
−1K060627Tag-IT Cystic Fibrosis KitTm Bioscience Corporation2006—
0 (this device)K083846Xtag Cystic Fibrosis 39 Kit V2, (CFTR 39 Kit V2), Model I027C0231, I027D0266…Luminex Molecular Diagnostics, Inc.2009—
FIG. 1 — Lineage of K083846, 2005–2009Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NUA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*DEN050004Tag-IT Cystic Fibrosis Kit
Our reading of the summary gave K043011, which is not in FDA’s 510(k) list. The device the summary names is FDA’s De Novo DEN050004, Tag-IT Cystic Fibrosis Kit (Tm Bioscience Corporation), granted May 9, 2005; older De Novo requests were first filed under a 510(k) number, so this links to the grant.
Tm Bioscience Corporation2005—
*K060627Tag-IT Cystic Fibrosis Kit
Summary page 3
…is Software (TDAS) CFTR Substantial Equivalence Information: 1. Predicatedevice name(s): xTAG® Cystic Fibrosis Kit 2. Predicate510(k) number(s): k043011, k060627 3. Comparison with predicate: Parameter xTAG Cystic Fibrosis 39 kit v2 xTAG…
Tm Bioscience Corporation2006—

Also cleared against DEN050004: 5 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 3.2 years on median.
  • None of the 2 ancestors has a recall.
  • 5 other devices also cite its predicate DEN050004.

How does its category compare?

All NUA devices

NUA System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection: FDA decisions, review times, recalls and adverse event reports over 20 years. 2009, this device’s year, is highlighted.

FDA decisions per year · NUA

2in 2016

2007: 12008: 12009: 42016: 2
2007high 4 (2009) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NUA

254in 2009

2009: 254 days median
2007high 254 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NUA

No recall names NUA since 2007.

Adverse event reports per year · NUA

1in 2013

2013: 1
2007high 1 (2013) · low 0 (2007)2025

MAUDE reports naming product code NUA, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20081—00
2009425400
20100—00
20110—00
20120—00
20130—01
20140—00
20150—00
20162—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

The xTAG® Cystic Fibrosis 39 kit v2 is a device used to simultaneously detect and identify a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human blood specimens. The panel includes mutations and variants currently recommended by the American College of MedicalGenetics and American College of Obstetricians and Gynecologists (ACMG/ACOG) plus some of the world's most common and North American…

Read the full statement (134 words)

The xTAG® Cystic Fibrosis 39 kit v2 is a device used to simultaneously detect and identify a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human blood specimens. The panel includes mutations and variants currently recommended by the American College of MedicalGenetics and American College of Obstetricians and Gynecologists (ACMG/ACOG) plus some of the world's most common and North American prevalent mutations. The xTAG® Cystic Fibrosis 39 kit v2 is a qualitative genotyping test which provides information intended to be used for carrier testing in adults of reproductive age, as an aid in newborn screening, and in confirmatory diagnostic testing in newborns and children.

The kit is not indicated for use in fetal diagnostic or pre-implantation testing. This kit is also not indicated for stand-alone diagnostic purposes.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K083846: Xtag Cystic Fibrosis 39 Kit V2, (CFTR 39 Kit V2), Model I027C0231, I027D0266, I027E0267.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K083846

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026